Intervention_1
DrugPostoperative administration of hydrocortisone for one month
NCT Number: NCT07558811
This multicenter randomized controlled trial plans to enroll primary aldosteronism (PA) patients who meet the following criteria: confirmed unilateral dominant secretion by adrenal vein sampling (AVS), willingness to undergo surgery, and coexisting chronic kidney disease (CKD). Participants will be randomly assigned in a 1:1 ratio to one of two groups. To determine whether short-term postoperative hydrocortisone replacement therapy (intervention group) is superior to conventional management (surgery within 7 days after AVS, control group) in terms of reducing the decline in estimated glomerular filtration rate (eGFR) at 12 months after surgery.
Trial opening soon.
Get Notified18 year–75 year
All sexes
Interventional
Phase 4
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Postoperative administration of hydrocortisone for one month
Time frame: the change in eGFR from baseline at 12 months post-surgery
To compare the change in eGFR from baseline at 12 months post-surgery between the conventional group and the intervention group.
Trial opening soon.
Get NotifiedRuijin Hospital
Other
Effects of Glucocorticoid Therapy on Renal Function in Patients With Primary Aldosteronism Complicated by Chronic Kidney Disease After Adrenalectomy: A Multicenter Randomized Controlled Trial
Acronym: GRAFT_PA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07687160
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Ottawa, Ontario, Canada
View Trial DetailsNCT07814105
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Shatin, Hong Kong
View Trial DetailsNCT07800858
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Cambridge, United Kingdom
View Trial DetailsNCT07796048
Adrenal Gland Diseases, Adrenocortical Hyperfunction
View Trial Details